Impact of insufficient drug efficacy of antiparkinson agents on patient’s quality of life: a cross-sectional study

Table 3 Patients’ Quality of Life based on the time zone showing insufficient efficacy of anti-parkinsonian medication

	Only in the daytime zone		In the time zone of sleeping and early morning with and without daytime		p value^a
	n	PDQ-8-SI	n	PDQ-8-SI	p value^a
	747	40.7 ± 19.2	924	43.4 ± 20.7	0.0092
Hoehn &Yahr stages
Stage I	13	28.6 ± 20.2	16	41.2 ± 22.4	0.1269
Stage II	49	35.9 ± 19.4	68	40.4 ± 21.4	0.2460
Stage III	319	37.6 ± 17.5	368	38.9 ± 17.4	0.3273
Stage IV	109	46.4 ± 17.6	136	49.9 ± 20.1	0.1460
Stage V	22	63.1 ± 22.0	33	71.3 ± 21.7	0.1761

Data excluding 41 patients without response on the time zones and with insufficient efficacy of medication. Data are expressed as numbers of patients , mean ± SD, or p values
^a:student t-test (comparison between the two groups)

ISSN: 1471-2377